Payment overview · 2025
General Payments
$246.04
9 reported records · 4 companies
Healthcare provider profile · identity verified
Inna Pildysh, DO
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1316914021
Verified facts
What the public records show
CMS Open Payments records show Inna Pildysh, DO received $246.04 in general payments during 2025 across 9 reported records.
Aimmune Therapeutics, Inc. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexium by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $95.39 | 38.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $74.50 | 30.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.05 | 22.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.10 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $246.04 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $95.39 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $74.50 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.05 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 181 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
181 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 997 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 876 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 791 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 639 | 86 |
| Carvedilol | Carvedilol | 555 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 530 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 525 | 59 |
| Metformin Hcl | Metformin Hcl | 459 | 64 |
| Dexlansoprazole Dr | Dexlansoprazole | 418 | 51 |
| Eliquis | Apixaban | 388 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 73 |
| Losartan Potassium | Losartan Potassium | 363 | 46 |
| Linzess | Linaclotide | 348 | 55 |
| Synthroid | Levothyroxine Sodium | 319 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 317 | 79 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 305 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 301 | 31 |
| Omeprazole | Omeprazole | 296 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 36 |
| Famotidine | Famotidine | 280 | 48 |
| Memantine Hcl Er | Memantine Hcl | 252 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 250 | 33 |
| Furosemide | Furosemide | 233 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 229 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 207 | 36 |
| Vascepa | Icosapent Ethyl | 190 | 35 |
| Memantine Hcl | Memantine Hcl | 184 | 32 |
| Zenpep | Lipase/Protease/Amylase | 181 | 37 |
| Ranolazine Er | Ranolazine | 176 | 17 |
| Creon | Lipase/Protease/Amylase | 168 | 32 |
| Jardiance | Empagliflozin | 158 | 24 |
| Nifedipine Er | Nifedipine | 152 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 27 |
| Gabapentin | Gabapentin | 147 | 20 |
| Glimepiride | Glimepiride | 141 | 13 |
| Allopurinol | Allopurinol | 131 | 20 |
| Glipizide Er | Glipizide | 130 | 14 |
| Telmisartan | Telmisartan | 129 | 19 |
| Valsartan | Valsartan | 129 | 16 |
| Glipizide | Glipizide | 125 | 16 |
| Finasteride | Finasteride | 119 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 81 |
| Repaglinide | Repaglinide | 109 | 16 |
| Azithromycin | Azithromycin | 104 | 83 |
| Enalapril Maleate | Enalapril Maleate | 102 | 13 |
| Ezetimibe | Ezetimibe | 100 | 12 |
| Januvia | Sitagliptin Phosphate | 98 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 95 | 12 |
| Ammonium Lactate | Ammonium Lactate | 95 | 34 |
| Ozempic | Semaglutide | 95 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 95 | 13 |
| Nitroglycerin Patch | Nitroglycerin | 93 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 93 | 13 |
| Atenolol | Atenolol | 92 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 92 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 90 | 17 |
| Single Use Swab | Alcohol Antiseptic Pads | 90 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 88 | 17 |
| Buspirone Hcl | Buspirone Hcl | 81 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 81 | suppressed |
| Simvastatin | Simvastatin | 80 | 17 |
| Meloxicam | Meloxicam | 79 | 36 |
| Entresto | Sacubitril/Valsartan | 77 | 16 |
| Donepezil Hcl | Donepezil Hcl | 76 | suppressed |
| Myrbetriq | Mirabegron | 74 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 73 | 24 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 69 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | suppressed |
| Repatha Sureclick | Evolocumab | 69 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 27 |
| Labetalol Hcl | Labetalol Hcl | 68 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 66 | 24 |
| Doxepin Hcl | Doxepin Hcl | 66 | 11 |
| Tradjenta | Linagliptin | 66 | suppressed |
| Trulicity | Dulaglutide | 65 | suppressed |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 64 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | suppressed |
| Loperamide | Loperamide Hcl | 56 | 20 |
| Lorazepam | Lorazepam | 54 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 54 | 14 |
| Tramadol Hcl | Tramadol Hcl | 53 | suppressed |
| Lisinopril | Lisinopril | 52 | suppressed |
| Dexilant | Dexlansoprazole | 50 | suppressed |
| Lidocaine | Lidocaine | 50 | suppressed |
| Ramipril | Ramipril | 50 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Gemtesa | Vibegron | 45 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 44 | suppressed |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Cefdinir | Cefdinir | 42 | 38 |
| Nitroglycerin | Nitroglycerin | 42 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Celecoxib | Celecoxib | 41 | 13 |
| Febuxostat | Febuxostat | 40 | suppressed |
| Felodipine Er | Felodipine | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | 11 |
| Clotrimazole | Clotrimazole | 39 | 20 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 20 |
| Digoxin | Digoxin | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Nystatin | Nystatin | 34 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 14 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Nexium | Esomeprazole Magnesium | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 31 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 24 |
| Cephalexin | Cephalexin | 28 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 19 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Praluent Pen | Alirocumab | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 13 |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Trulance | Plecanatide | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Crestor | Rosuvastatin Calcium | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 14 |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Atelvia | Risedronate Sodium | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Micardis Hct | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Prevacid | Lansoprazole | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Norpace | Disopyramide Phosphate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Plavix | Clopidogrel Bisulfate | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Rapaflo | Silodosin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Diovan | Valsartan | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | 11 |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $246.04 · 9 records | Aimmune Therapeutics, Inc. | BREZTRI, GEMTESA, OTEZLA, REPATHA, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error